Pfizer Says FDA Approves Padcev Plus Keytruda For Muscle-Invasive Bladder Cancer Regardless Of Cisplatin Eligibility
PFE•FDA approves Padcev plus Keytruda for bladder cancer
- U.S. FDA approves Padcev® plus Keytruda® as neoadjuvant and adjuvant treatment for muscle-invasive bladder cancer regardless of cisplatin eligibility.
